None listed
Conditions
Interventions
Drug : The newly added SGLT-2 inhibitor is administered with a usage approved by the Ministry of Food and Drug Safety.
Sponsors
Kangbuk Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Type 2 diabetes ? Between 19 and 70 years of age ? HbA1c >7.0% ? Patients without stable drug treatment or drug treatment history for more than 3 months. ? Subjects who have understood the contents of the clinical trial and voluntarily consented in writing ? Can write a diary well and agree to it
Exclusion criteria
Exclusion criteria: ? Patients with a history of prescribing SGLT-2 inhibitors within 3 months ? Patients with a history of taking an appetite suppressant or GLP-1 agonist within 3 months ? Anemia (hemoglobin outside the normal range) ? People with a form of gastrointestinal disease that can affect appetite changes ? Liver disease (Alanine Aminotransferase, ALAT) and/or serum aspartaaminotransferase (ASAT) > 2 times normal) or history of liver disease ? Renal disease eGFR by MDRD equation less than 45 mL/min/1.73 m2 ? Anorexia, bulimia, or bulimia ? When the investigator determines that physical or psychological circumstances may prevent participation in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare and evaluate changes in app-based dietary habits (total intake calories, frequency of hunger, frequency of food intake, and changes in dietary patterns) between groups with and without appropriate blood glucose changes after the addition of new diabetes medication | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison and assessment of changes in app-based dietary habits (total intake calories, frequency of hunger, frequency of food intake, etc.) and changes in dietary intake (visual analogue scale) according to weight changes after the addition of new diabetes medication;Comparison of changes in nutritional composition (carbohydrate, fat, protein) between groups with appropriate blood sugar changes and those with no appropriate blood sugar changes after the addition of new diabetes medication | — |
Countries
Korea, Republic of
Contacts
Public ContactSangmo Hong
Hanyang University Guri Hospital
Outcome results
None listed